Design, synthesis and biological evaluation of 2,4-pyrimidinediamine derivatives as ALK and HDACs dual inhibitors for the treatment of ALK addicted cancer
Simultaneous inhibition of histone deacetylases (HDACs) and anaplastic lymphoma kinase (ALK) could enhance therapeutic activity against ALK addicted cancer cells. Herein, a new series of 2,4-pyrimidinediamine derivatives as ALK and HDACs dual inhibitors were designed, synthesised and evaluated. Comp...
Saved in:
Main Authors: | Dafeng Guo (Author), Yu Yu (Author), Binyu Long (Author), Ping Deng (Author), Dongzhi Ran (Author), Lei Han (Author), Jiecheng Zheng (Author), Zongjie Gan (Author) |
---|---|
Format: | Book |
Published: |
Taylor & Francis Group,
2022-12-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
mRNA Expression Level of ALK in Neuroblastoma Is Associated with Histological Subtype, ALK Mutations and ALK Immunohistochemical Protein Expression
by: Rixt S. Bruinsma, et al.
Published: (2024) -
Discovery of novel anaplastic lymphoma kinase (ALK) and histone deacetylase (HDAC) dual inhibitors exhibiting antiproliferative activity against non-small cell lung cancer
by: Kang-Li Wang, et al.
Published: (2024) -
Uterine mesenchymal tumors harboring ALK fusions and response to ALK-targeted therapy
by: Chrisann Kyi, et al.
Published: (2021) -
ALK positive histiocytosis in an adult female with an EML4-ALK RNA fusion
by: Jay Mehta, et al.
Published: (2020) -
Concomitant novel ALK-SSH2, EML4-ALK and ARID2-ALK, EML4-ALK double-fusion variants and confer sensitivity to crizotinib in two lung adenocarcinoma patients, respectively
by: Hong Tao, et al.
Published: (2022)